Navigation Links
Telik Announces Ezatiostat (Telintra®) Preclinical Presentation at the 2011 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
Date:11/1/2011

PALO ALTO, Calif., Nov. 1, 2011 /PRNewswire/ -- Telik, Inc. (Nasdaq: TELK) announced today the presentation of mechanistic studies on Telintra and related analogs at the 2011 Meeting of the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in San Francisco, California.  Details of the presentation are as follows:


  • Novel Ezatiostat analogues disrupt binding of GSTP1 to all three major MAP kinases (JNK, ERK and p38) and exhibit context-dependent antitumor activity; Ali-Osman, F., Okamura, T., Turley, R., Barker, A.,  Keck, J.,  Laborde, E.,  Cai, D.,  Macsata, R.Abstract B229 – PO 70, Therapeutic Agents: Small Molecule Kinase Inhibitors 2, Monday, November 14, 12:30-2:30 PM and 6:00-7:30 PM.These studies were conducted by Professor Francis Ali-Osman, Director, Experimental Therapeutics Program, Duke Comprehensive Cancer Center, and expand our understanding of the novel mechanism of action of Telintra.  Telintra and related analogues, through their inhibition of the enzyme GSTP1, were able to affect the activity of all three major MAP kinases, signaling proteins that are critical for the control of cellular growth, differentiation and apoptosis.  Significant anti-tumor activity was also observed in human cancer cells derived from brain cancer, breast cancer and melanoma.  Telintra has demonstrated positive clinical activity in patients with myelodysplastic syndrome (Blood 2009, 113[26]:6533-6540; Cancer 2011, doi: 10.1002/cncr.26469), and is currently in clinical development (Clintrials.gov).

    About Telik

    Telik, Inc. of Palo Alto, CA, is a clinical stage drug development company focused on discovering and developing small molecule drugs to treat cancer.  The company's most advanced drug candidate is Telintra, a modified glutathione analog intended for the treatment of hematologic malignancies including myelodysplastic syndrome; followed by Telcyta®, a cancer activated prodrug for the treatment of a variety of cancers. Telik's product candidates were discovered using its proprietary drug discovery technology, TRAP®, which enables the rapid and efficient discovery of small molecule drug candidates.

    Telik, the Telik logo, TELINTRA, TELCYTA and TRAP are trademarks or registered trademarks of Telik, Inc.


    '/>"/>

  • SOURCE Telik, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Related medicine technology :

    1. Telik Announces Presentation of Preclinical Data on Dual Inhibitors of Aurora Kinases and VEGFR2
    2. Telik Announces Preclinical Data Demonstrating Anti-Cancer Activity of Dual Inhibitors of Aurora Kinase and VEGFR2
    3. Telik Announces Telintra Presentation at American Society of Hematology Annual Meeting
    4. Telik Announces Initiation of Two Phase 2 Randomized TELINTRA Studies
    5. Teliks Proteasome Inhibitor Program Meets a Preclinical Development Milestone
    6. Telik Announces Presentation at ASCO Annual Meeting
    7. Telik Announces Publication of Positive Phase 1 Results of a Multicenter Study of Ezatiostat Hydrochloride (TELINTRA(R), TLK199) Tablets In Patients With Myelodysplastic Syndrome
    8. Telik Announces Publication of Positive Phase 1-2a Results of a Multicenter Study of TELCYTA(R) in Combination With Carboplatin and Paclitaxel in Patients With Advanced Non-Small Cell Lung Cancer
    9. Telik Announces Initiation of Phase 1 Clinical Study of Ezatiostat Hydrochloride (TELINTRA(R), TLK199) Tablets in Combination With Lenalidomide (Revlimid(R)) in Patients With Myelodysplastic Syndrome (MDS)
    10. Telik Announces Third Quarter 2009 Financial Results
    11. Telik Announces Fourth Quarter and 2009 Year End Financial Results and 2010 Financial Guidance
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:6/26/2016)... , June 26, 2016 ... care operating models within the health care industry is ... financial efficiency , Deloitte offers a suite of ... business issues impacting efficient cost optimization: labor resource analysis, ... These services facilitate better outcomes and better economics ...
    (Date:6/24/2016)... , June 24, 2016   Bay ... Rehabilitation Network,s Dean Center for Tick Borne ... Medicine and Rehabilitation, MIT Hacking Medicine, University of ... Innovation, today announced the five finalists of ... Lyme disease.  More than 100 scientists, clinicians, researchers, ...
    (Date:6/24/2016)... Dehaier Medical Systems Ltd. (NASDAQ: ... and sells medical devices and wearable sleep respiratory products ... cooperation agreement with Hongyuan Supply Chain Management Co., Ltd. ... 20, 2016, to develop Dehaier,s new Internet medical technology ... will leverage Hongyuan Supply Chain,s sales platform to reach ...
    Breaking Medicine Technology:
    (Date:6/26/2016)... Lake Orion, Clarkston, Michigan (PRWEB) , ... June ... ... direction with respect to fertility once they have been diagnosed with endometriosis. These ... tolerable intercourse but they also require a comprehensive approach that can help for ...
    (Date:6/25/2016)... ... June 25, 2016 , ... "With 30 hand-drawn hand gesture ... said Christina Austin - CEO of Pixel Film Studios. , ProHand Cartoon’s package ... Final Cut Pro X . Simply select a ProHand generator and drag it ...
    (Date:6/25/2016)... ... June 25, 2016 , ... On Friday, June 10, Van Mitchell, Secretary of ... award to iHire in recognition of their exemplary accomplishments in worksite health promotion. , ... Workplace Health & Wellness Symposium at the BWI Marriott in Linthicum Heights. iHire was ...
    (Date:6/24/2016)... ... 2016 , ... June 19, 2016 is World Sickle Cell Observance Day. In ... benefits of holistic treatments, Serenity Recovery Center of Marne, Michigan, has issued ... Sickle Cell Disease (SCD) is a disorder of the red blood cells, which can ...
    (Date:6/24/2016)... ... June 24, 2016 , ... ... micro-osteoperforation for accelerated orthodontic treatment. Dr. Cheng has extensive experience with all areas ... , AcceleDent, and accelerated osteogenic orthodontics. , Micro-osteoperforation is a revolutionary adjunct ...
    Breaking Medicine News(10 mins):